BCI
ADPT icon

Brinker Capital Investments’s Adaptive Biotechnologies ADPT Stock Holding History

Brinker Capital Investments’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,202
Closed -$603K – 1165
2020
Q4 		$603K Buy
10,202
+5,270
+107% +$272K 0.01% 798
2020
Q3 		$240K Buy
+4,932
New +$207K ﹤0.01% 1063

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brinker Capital Investments's ADPT Position: Q1 2021 in Review

Brinker Capital Investments sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 10,202 shares — an estimated $603K sold.

Brinker Capital Investments first reported a position in ADPT in Q3 2020 and held it in 2 quarters. The position peaked at $603K in Q4 2020. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

  • Brinker Capital Investments reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Brinker Capital Investments sold 10,202 Adaptive Biotechnologies shares in Q1 2021, an estimated $603K.
  • Brinker Capital Investments first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 2 quarters.
  • Brinker Capital Investments's Adaptive Biotechnologies position peaked at $603K in Q4 2020.
  • 248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on Brinker Capital Investments's 13F filing for Q1 2021, filed 12 May 2021.